ClinicalTrials.gov record
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
ClinicalTrials.gov ID: NCT02792231
Public ClinicalTrials.gov record NCT02792231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Study identification
- NCT ID
- NCT02792231
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 955 participants
Conditions and interventions
Conditions
Interventions
- Matching placebo of ofatumumab subcutaneous injections Drug
- Ofatumumab subcutaneous injection Drug
- Teriflunomide capsule Drug
- Teriflunomide-matching placebo capsules Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2016
- Primary completion
- Jul 9, 2019
- Completion
- Oct 21, 2020
- Last update posted
- Nov 21, 2021
2016 – 2020
United States locations
- U.S. sites
- 59
- U.S. states
- 23
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35233-0271 | — |
| Novartis Investigative Site | Cullman | Alabama | 35058 | — |
| Novartis Investigative Site | Tucson | Arizona | 85704 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Basalt | Colorado | 81621 | — |
| Novartis Investigative Site | Boulder | Colorado | 80301 | — |
| Novartis Investigative Site | Centennial | Colorado | 80112 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative Site | Denver | Colorado | 80210 | — |
| Novartis Investigative Site | Fort Collins | Colorado | 80528 | — |
| Novartis Investigative Site | Fort Collins | Colorado | 907-280528 | — |
| Novartis Investigative Site | Fairfield | Connecticut | 06824 | — |
| Novartis Investigative Site | Newark | Delaware | 19713 | — |
| Novartis Investigative Site | Bradenton | Florida | 34205 | — |
| Novartis Investigative Site | Gainesville | Florida | 32611 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Ocala | Florida | 34471 | — |
| Novartis Investigative Site | Oldsmar | Florida | 34677 | — |
| Novartis Investigative Site | Ormond Beach | Florida | 32174 | — |
| Novartis Investigative Site | Palm Coast | Florida | 32164 | — |
| Novartis Investigative Site | Sarasota | Florida | 34243 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33713 | — |
| Novartis Investigative Site | Tallahassee | Florida | 32312 | — |
| Novartis Investigative Site | Tampa | Florida | 33603 | — |
| Novartis Investigative Site | Tampa | Florida | 33609 | — |
| Novartis Investigative Site | Tampa | Florida | 33612 | — |
| Novartis Investigative Site | Suwanee | Georgia | 30024 | — |
| Novartis Investigative Site | Anderson | Indiana | 46011 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | Wellesley | Massachusetts | 02481 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | Golden Valley | Minnesota | 55422 | — |
| Novartis Investigative Site | Billings | Montana | 59101 | — |
| Novartis Investigative Site | Great Falls | Montana | 59405 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-0001 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28806 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28202 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27405 | — |
| Novartis Investigative Site | Akron | Ohio | 44320 | — |
| Novartis Investigative Site | Columbus | Ohio | 43214 | — |
| Novartis Investigative Site | Columbus | Ohio | 43221 | — |
| Novartis Investigative Site | Westerville | Ohio | 43081 | — |
| Novartis Investigative Site | Portland | Oregon | 97225 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novartis Investigative Site | Willow Grove | Pennsylvania | 19090 | — |
| Novartis Investigative Site | Greer | South Carolina | 29650 | — |
| Novartis Investigative Site | Cordova | Tennessee | 38018 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37922 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37205 | — |
| Novartis Investigative Site | Greenville | Texas | 75401 | — |
| Novartis Investigative Site | Lubbock | Texas | 79410 | — |
| Novartis Investigative Site | Sherman | Texas | 75092 | — |
| Novartis Investigative Site | Orem | Utah | 84058 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84103 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Kirkland | Washington | 98034 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
| Novartis Investigative Site | Tacoma | Washington | 98405 | — |
| Novartis Investigative Site | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02792231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2021 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02792231 live on ClinicalTrials.gov.